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Expression of HIV-1 genes in podocytes alone can lead to the
full spectrum of HIV-1–associated nephropathy.
Background. Human immunodeficiency virus (HIV)-1–
associated nephropathy (HIVAN) is characterized by col-
lapsing focal and segmental glomerulosclerosis (FSGS) and
microcystic tubular dilatation. HIV-1 infection is also associ-
ated with other forms of nephropathy, including mesangial hy-
perplasia. Since HIV-1 gene products are detected in podocytes
and other renal cells, it remains uncertain whether podocyte-
restricted HIV-1 gene expression can account for the full spec-
trum of renal lesions involving nonpodocytes.
Methods. To define the role of podocyte-restricted HIV-1
gene expression in the progression of HIVAN, we generated
transgenic mice that express nonstructural HIV-1 genes selec-
tively in podocytes.
Results. Four of the seven founder mice developed protein-
uria and nephropathy. In a subsequently established transgenic
line, reverse transcription-polymerase chain reaction (RT-PCR)
analysis detected mRNAs for vif , vpr, nef , and spliced forms
of tat and rev, but not vpu, in the kidney. In situ hybridiza-
tion localized HIV-1 RNA to the podocyte. Transgenic mice on
FVB/N genetic background exhibited cuboidal morphology of
podocytes with reduced extension of primary and foot processes
at 2 weeks of age. After 3 weeks of age, these mice developed
massive and nonselective proteinuria with damage of podocytes
and other glomerular cells and, after 4 weeks of age, collapsing
FSGS and microcystic tubular dilatation. In marked contrast,
transgenic mice with C57BL/6 genetic background showed ei-
ther normal renal histology or only mild mesangial expansion
without overt podocyte damage.
Conclusion. The present study demonstrates that podocyte-
restricted expression of HIV-1 gene products is sufficient for
the development of collapsing glomerulosclerosis in the setting
of susceptible genetic background.
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Podocytes, or glomerular visceral epithelial cells, play
a critically important role as the filtration barrier of
the glomerulus [1]. Moreover, it has been observed in
many clinical and experimental settings that podocyte
injury precedes glomerulosclerosis, a morphologic hall-
mark of end-stage renal failure [2–5]. Recent studies in
humans and gene-targeted mice revealed that mutations
in molecules which have important roles in podocytes,
including nephrin, podocin, CD2-associated protein and
a-actinin-4, result in proteinuria and glomerulosclerosis
[6–12]. These findings indicate that injury of podocytes
can trigger the sequence of pathologic events leading to
glomerulosclerosis [10, 13–15].
Human immunodeficiency virus (HIV)-1–associated
nephropathy (HIVAN) affects up to 10% of HIV-1–
infected individuals with a marked racial predilection
for black and Hispanic people [5, 16–21]. HIVAN is
characterized by severe podocyte alterations, heavy pro-
teinuria, and rapid progression to end-stage renal fail-
ure. Pathologically, HIVAN is characterized at late stage
by collapsing focal and segmental glomerulosclerosis
(FSGS) and tubulointerstitial changes, including micro-
cystic tubular dilation. Podocytes are dedifferentiated
with loss of synaptopodin and Wilms tumor (WT)-1 pro-
liferate and undergo apoptosis [22–24]. HIV-1 mRNA
and DNA have been detected in epithelial cells, includ-
ing podocytes, parietal epithelial cells, and tubular cells, in
HIVAN [25–28]. Although HIVAN is the most common
renal complication in HIV-1–infected patients, HIV-1 in-
fection is also associated with other forms of renal dis-
eases, including minimal change nephropathy, mesangial
hyperplasia, and immune-mediated glomerulonephritis
[16, 19, 29, 30]. The latter lesions are more common in
HIV-1–infected Caucasians [29].
Studies using transgenic animals have provided impor-
tant insights into HIVAN pathogenesis. Tg26, a trans-
genic mouse line carrying HIV-1 proviral DNA defective
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for gag and pol, developed nephropathy similar to
HIVAN in humans [31, 32]. In these mice, the transgene
expression is driven by the authentic viral promoter, LTR,
and occurs in various organs [31]. In the kidney, trans-
gene expression was detected in podocytes, glomerular
parietal epithelial cells, and various parts of tubular cells
[26, 33, 34]. Similar to HIVAN in humans, glomeruli in
Tg26 transgenic mice showed collapsing FSGS, accom-
panied by proliferation, dedifferentiation, and apopto-
sis of podocytes. The tubulointerstitial changes included
microcystic dilatation, proliferation, and apoptosis of
tubular cells [33, 34]. Renal cross-transplantation exper-
iments between transgenic and wild-type mice indicated
that HIV gene products generated in the kidney cause
nephropathy independently of circulating viral proteins
or dysregulated cytokines [34]. The same transgene con-
struct also caused nephropathy similar to human HIVAN
in rats [35, 36]. These studies in humans and animal mod-
els indicate that HIV-1 gene products generated in renal
cells, including podocytes and tubular cells, directly cause
nephropathy.
In addition, other transgenic lines, CD4C/HIV and
CD4C/simian immunodeficiency virus (SIV), respec-
tively, expressing HIV Nef or SIV Nef under the control
of the CD4C regulatory elements, developed segmental
glomerulosclerosis, tubulointerstitial nephritis, and mi-
crocystic dilatation [37–41]. These CD4C sequences rep-
resent a chimeric construct of the human CD4C promoter
and the mouse CD4 enhancer and have been shown to
drive expression of surrogate genes in mature and imma-
ture CD4+ T cells and in cells of the macrophage/myeloid
lineage [37, 42–44]. The interstitial nephritis in this line
was alleviated by an Ij-B kinase inhibitor, in association
with reduction in regulated upon activation, normal T-cell
expressed and secreted (RANTES) [45], suggesting that
inflammatory cytokines induced by HIV-1 gene products
may be involved in the development of the renal disease
in these transgenic mice.
In the present study, to further delineate the direct ef-
fect of HIV-1 genes on podocytes, and to define the role
of podocyte dysregulation in the progression of HIVAN,
we have generated transgenic mice expressing HIV-1 ge-
nomic DNA selectively in podocytes, utilizing the pro-
moter of the mouse nephrin gene, Nphs1.
METHODS
Generation of transgenic mice
The transgene was constructed from mutant B, a mu-
tant HIV-1 genome used in a previous study [45]. Mutant
B was derived from NL4-3 (GeneBank M1992) and has
a point mutation in env. The BssHII-Aat II fragment
of mutant B, which contains all HIV-1 coding regions,
nucleotide (nt) 711-9562, and a polyadenylation signal of
SV40, was subcloned into pBR322. From this DNA, the
portion spanning from Sph1 (nt 1443) to Bal1 (nt 4551)
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Fig. 1. Generation of podocyte specific HIV-1 transgenic mice. (A)
Structure of the transgene. The transgene, depicted by the top line, con-
sisted of a 5.4 kb Nphs1 promoter, a fragment of NL4-3 proviral DNA
and a poly A signal from SV40 DNA. Some key restriction enzyme
sites and nucleotide numbers (nt) according to the GeneBank M1992
are shown. The NL4-3 DNA fragment spans nt 711-9562, with a dele-
tion of nt 1443-4551 (gag and pol are disrupted) and a point mutation
at 4551 in env as depicted by X. The resultant transgene encodes vif ,
vpr, vpu, tat, rev, and nef . The position of each gene is shown by open
boxes. Dashed lines represent the intron of tat and rev. The bold bars
show the positions of the probes for in situ hybridization and Northern
blot analysis. The thin lines shown below depict positions of mRNAs
detected by reverse transcription-polymerase chain reaction (RT-PCR)
in the kidney of HIV13 transgenic mice. The portion of the intron of
tat and rev, shown by dashed lines, was not detected by RT-PCR. (B)
Representative results of RT-PCR for HIV-1 mRNA. +, reaction with
RT; −, reaction without RT; N, negative control using wild-type ge-
nomic DNA as a template; P, positive control using transgenic genomic
DNA as a template. HIV-1 mRNA was detected in the RNA from the
kidneys of HIV13FBV and HIV13B6, but not in those from HIV43,
HIV73 or wild-type mice. (C) Northern blot analysis for HIV-1 mRNA
in the founder transgenic mice. A 32P-labeled DNA fragment including
nef was used as a probe [shown in (A)]. Specific signal was detected in
HIV13, HIV51, and HIV52, and faintly in HIV34 (arrowhead), but not
in HIV43, HIV73, or wild-type mice.
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Table 1. Polymerase chain reaction (PCR) primers used in this study
Name Primer sequence (5′-3′) Position
vif4 GTACTTGGCACTAGCAGCATT 5073–5094
vif3 GCAAGTAGACAGGATGAGGATT 5478–5498
vif5 CTTGTTCCATCTGTCCTCTGT 5568–5548
vpr1 TGAAACTTACGGGGATACTTGG 5699–5720
vpr2 GTCGAGTAACGCCTATTCTGC 5814–5794
vpr5 CCCAAGTATCCCCGTAAGTTT 5721–5701
tat1 AGACTAGAGCCCTGGAAGCATC 5848–5869
tat5 CTTCTATTCCTTCGGGCCTGTC 8417–8396
rev1 CGTCCCAGATAAGTGCTAAGGATC 8489–8466
vpu1 AAAGAGCAGAAGACAGTGGCAAT 6200–6222
vpu2 CATTTCCACCCCCATCTCCACA 6270–6249
nef3 TAAGGGAAAGAATGAGACGAGC 8833–8854
nef4 ACTCTAACACTTCTCTCTCAGG 9312–9333
nef6 GGAAAGAATGAGACGAGCTG 8837–8856
nef8 ATTCCATGCAGGCTCACAGG 9285–9304
was deleted to disrupt gag and pol. The resultant frag-
ment was combined with a 5.4 kb promoter region of
Nphs1 (Fig. 1A).
The transgene DNA was microinjected into fertilized
eggs obtained from mating between DBF1 and C57BL/6
mice. Transgenic mice were identified by polymerase
chain reaction (PCR) performed on genomic DNA from
the tail, using primers, nef3 and nef4. The genotype was
confirmed by Southern analysis. Founder transgenic mice
were mated with wild-type C57BL/6N or FVB/N mice.
Detection of the transgene expression
PolyA-RNA was isolated from the whole kidney using
Micro-Fast Track Kit (Invitrogen, Carlsbad, CA, USA).
Northern analysis was performed using a DNA probe (nt
8465-9562) (Fig. 1A). The following primer sets were used
to detect HIV-1 gene products by reverse transcription
(RT)-PCR: vif4 and vif5, vif4 and vpr5, vif3 and vpr5,
vpr1 and vpr2, tat1 and rev1, vif4 and tat5, vif3 and tat
5, nef3 and nef4, nef6 and nef8, and vpu1 and vpu2. The
positions of these primers are listed in Table 1.
In situ hybridization was carried out using an RNA
probe that covers a 3′ end of the HIV-1 coding region
(nt 8465-9562) (Fig. 1A) as previously reported [46]. 35S-
labeled sense and antisense probes were generated using
MAXISCRIPTTM In Vitro Transcription Kit (Ambion,
Austin, TX, USA). Each probe was sheared by alkaline
hydrolysis to yield RNA about 150 bp in length.
Animal experiments
The Animal Experimentation Committee of Tokai
University Medical School and the Institutional Animal
Care and Use Committee of Vanderbilt University Medi-
cal Center approved the protocol, in accordance with the
principles and procedures outlined in the National Insti-
tute of Health Guide for the Care and Use of Laboratory
Animals.
Fourteen HIV13FVB mice and 14 wild-type littermates
were followed up to 18 weeks of age. These were sacri-
ficed when they showed clinical signs of wasting. In ad-
dition, for histologic analysis, the following numbers of
HIV13FVB mice and wild-type littermates, respectively,
were sacrificed at the indicated time points: 4 and 5, at
1 week of age, 4 and 5 at 2 weeks of age, 18 and 14 at 3
weeks of age, and 8 and 5 at 4 weeks of age.
Fifty-five HIV13B6 mice and 50 wild-type littermates
were followed up to 18 weeks of age for the survival rate.
The following numbers of HIV13B6 mice and wild-type
littermates, respectively, were analyzed for histology at
the indicated time points: 6 and 6 at 2 weeks of age, 2 and
2 at 5 weeks of age, 2 and 2 at 6 weeks of age, 5 and 5 at
9 weeks of age, and 12 and 12 after 6 months of age.
Twenty-four–hour urine specimens were collected in
metabolic cages. Concentrations of total protein and
creatinine in the urine were determined with an au-
tomatic analyzer (SRL, Tokyo, Japan). Urine samples
(2 lL) were analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) using
2% to 15% gradient gel.
Morphologic analysis
For routine histology and immunostaining, kidneys
were fixed in 4% buffered paraformaldehyde (PFA)
and embedded in paraffin. For transmission electron mi-
croscopy, kidneys were fixed in 2.5% glutaraldehyde/
0.05 mol/L phosphate buffer at 4◦C for overnight, washed
in 0.1 mol/L phosphate buffer, further fixed in 1%
OsO4/0.05 mol/L phosphate buffer and dehydrated in se-
rial graded ethanol and acetone. For scanning electron
microscopy, tissue pieces were fixed in glutaraldehyde,
dehydrated in ethanol, fractured with a knife, prepared
with a critical point drier, and coated with gold using
an ion sputter. The fractured surface was observed with
15 kV acceleration voltage.
Glomerular maturity index was determined at 2 weeks
of age as previously described [46].
Immunostaining
The following primary antibodies were used in the
present study: monoclonal antirat synaptopodin (Pro-
gen, Heidelberg, Germany), monoclonal antidesmin
(1:50) (DakoCytomation, Kyoto, Japan), monoclonal
anti-Ki-67 (1:200) (Novocastra Laboratories Ltd., New-
castle, UK), rabbit antihuman WT-1 (1:100) Santa Cruz
Biotechnology, Santa Cruz, CA, USA), rabbit antiker-
atin/cytokeratin (1:100) (Nichirei, Tokyo, Japan), goat an-
timouse IgG (1:20) (ICN, Aurora, OH, USA), goat anti-
mouse IgM (1:50) (ICN), goat antimouse IgA (1:2000)
(ICN), goat antimouse complement C3 (1:1000) (ICN),
and goat antimouse fibrinogen antibody (Nordic Im-
munology, Tilburg, The Netherlands). In addition, the
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Table 2. Summary of HIV-1 founder transgenic mice
Urinary protein/ Transgene Renal histology of
Mouse Gender creatinine(age)a Renal histology Survival time expressionb transgenic offspring
HIV13 M 22.9 (6 months) Mild FSGS >13 months (+) FSGS
HIV34 F 13.1 (6 weeks) ND 10 months (+) FSGS
HIV42 F ND ND 30 days ND No offspring
HIV43 M 12.8 (6 months) Normal >13 months (−) Normal
HIV51 M 25.3 (6 months) Normal >6 months (+) No offspring
HIV52 M 44.7 (6 months) FSGS >6 months (+) No offspring
HIV64 F 62.7 (6 weeks) FSGS 52 days (+) No offspring
HIV73 F 12.6 (6 months) Normal >13 months (−) Normal
FSGS is focal segmental glomerulosclerosis; ND is not determined.
aThe concentration ratio of total urinary protein (mg/mL) to urinary creatinine (mg/mL). Values in bold letters indicate significant elevation compared to age- and
gender-matched wild-type mice.
bTransgene expression determined by reverse transcription-polymerase chain reaction (RT-PCR) on total RNA extracted from the kidney.
following antibodies were obtained from the NIH AIDS
Research and Reference Reagent Program and used
in the present study: monoclonal anti-NEF (AG11 and
AE6), monoclonal anti-TAT (NT3 2A4.1 and NT3 5A
5.3), monoclonal anti-VIF (319), monoclonal anti-REV
(1G7), monoclonal anti-TAT (1D9), rabbit anti-VIF and
rabbit anti-VPR. For synaptopodin, desmin, Ki-67, and
WT-1, tissues were heated by microwave. For cytokeratin,
tissues were pretreated with 0.1% trypsin for 10 minutes
at 37◦C. No staining was detected without primary anti-
bodies.
Statistics
Results are expressed as mean ± standard error. Data
were analyzed by unpaired t test. Differences were con-
sidered to be statistically significantly at P < 0.05.
RESULTS
Generation of transgenic mice expressing HIV-1 genes in
the kidney
We constructed a transgene by combining a promoter
fragment of Nphs1, which directs podocyte-specific ex-
pression, and HIV-1 proviral DNA with mutations in gag,
pol, and env. The resulting transgene encodes vpr, vif , tat,
rev, nef , and vpu.
We obtained eight founder transgenic mice (Table 2).
One founder mouse, coded HIV42, showed severe
growth retardation and died at 30 days of age before anal-
ysis. The remaining seven mice were analyzed. The devel-
opment of nephropathy in Tg26 line has been reported to
be dependent on FVB/N genetic background. We, there-
fore, mated these founder mice with both C57BL/6 and
FVB/N mice.
Overall, of the seven transgenic mice analyzed, four
developed nephropathy. One founder mouse, HIV13,
did not show proteinuria and survived for more than
13 months. Histologic analysis at 13 months of age showed
focal intratubular casts and sclerosis in a few glomeruli.
The HIV13 founder mouse generated many transgenic
offspring, which were analyzed in detail as described be-
low. Most transgenic mice generated by mating HIV13
and FVB/N mice (designated as HIV13FVB) developed
collapsing FSGS, whereas those generated by mating with
C57BL/6 mice (designated as HIV13B6) showed no or
very mild renal lesions.
Two other founder transgenic mice, HIV64 and
HIV52, developed proteinuria and nephropathy similar
to HIV13FVB. No offspring was obtained from these
mice. HIV34 mice showed slightly elevated urinary pro-
tein/creatinine ratios at 6 weeks of age and died at
10 months of age without morphologic analysis. Two
transgenic offspring were obtained from mating with
C57BL/6 mice. These showed proteinuria after 7 weeks of
age, and morphologic analysis done at 2 and 12 months of
age revealed nephropathy similar to that in HIV13FVB.
Three other founder transgenic mice, HIV43, 51 and 73,
showed no proteinuria and normal renal histology. Trans-
genic offspring obtained by mating HIV43 or HIV73 with
FVB/N or C57BL/6 mice showed normal renal histol-
ogy without proteinuria. No offspring was obtained from
HIV51.
Expression of the transgene
We analyzed transgene expression by RT-PCR using
primers, nef3 and nef4, or nef6 and nef8, on polyA RNA
extracted from the kidney. In transgenic mice of lines
13 and 34, and the HIV51 and HIV52 founder mice,
the transgene mRNA was readily detected. However,
in transgenic mice of lines 43 and 73, transgene expres-
sion was only marginally detectable by RT-PCR (Fig. 1B)
(Table 2). As expected from the podocyte-specific activ-
ity of the nephrin promoter, the transgene mRNA was
not detected in other organs, including the liver, spleen,
intestine, colon, heart, and lung (data not shown).
Northern blot analysis confirmed that HIV-1 RNA was
expressed in the kidneys of transgenic mice of lines 13
and 34, and the HIV51 and HIV52 founder mice, but not
in wild-type mice or transgenic mice of lines 43 and 73
(Fig. 1C). The size of the main transcript was about 3 kb.
HIV52, which expressed the highest level of HIV-1 RNA,
showed an additional larger transcript.
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Wild-type Transgenic
Fig. 2. In situ hybridization for HIV-1 mRNA in HIV13 mice. HIV-
1 mRNA was localized to the periphery of the glomeruli [i.e., on
podocytes in transgenic mice (C, arrowheads, and D)], whereas it was
not detectable in wild-type mice (A and B). Sense probe showed no
significant signals (not shown) [(A and C) low magnification (×200);
(B and D) high magnification (×400)].
We further analyzed RNA of transgenic offspring of the
founder mice HIV13 by RT-PCR using various primers
listed in Table 1. As shown in Figure 1A, mRNAs for vif ,
vpr, tat, rev, and nef, but not vpu, were detected. mRNAs
of tat and rev were spliced at nt 6044 and nt 8369, and
unspliced forms were not detected.
The level of viral protein expression was below that
detectable by immunostaining using antibodies against
NEF, TAT, VPR, REV, or VIF. In situ hybridization per-
formed on the kidneys of line HIV13 transgenic mice re-
vealed that HIV-1 RNA expression was confined within
the glomerulus. It was localized to the periphery of the
glomerular capillary tuft corresponding to podocytes, but
not along Bowman’s capsule (Fig. 2). No specific signal
was detected with the sense probe.
Nephrotic syndrome and survival in HIV13FBV
vs. wild-type mice
Most HIV13FVB mice developed proteinuria around
3 weeks of age (Fig. 3A). SDS-PAGE analysis of the urine
showed that proteinuria was non-selective (Fig. 3C). We
longitudinally followed 14 HIV13FBV mice and 14 wild-
type littermates. After 3 weeks of age, HIV13FVB mice
showed growth retardation. The mean body weight of
HIV13FVB was less than 80% of that of wild-type litter-
mates at 4 weeks of age. They began to die after 4 weeks of
age and exhibited 71% mortality within 18 weeks (Fig. 4).
Two of the 4 HIV13FVB mice that survived for 18 weeks
also showed proteinuria and nephropathy on histologic
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Fig. 3. Proteinuria in HIV13 mice. (A and B) The ratio of total uri-
nary protein (mg/mL) to urinary creatinine (mg/mL) (Uprot/Cr) was
determined with 24-hour urine samples from (A) HIV13FVB and (B)
HIV13B6 mice. T, transgenic mice; W, wild-type mice. ∗P < 0.05 vs.
wild-type. Mean values (long bars) ± SE (short bars) are shown for
male wild-type mice at 3 and 4 weeks of age and female wild-type mice
at all ages. For transgenic mice and older wild-type males, individual
measurements (◦) and mean values (–) are shown. Numbers above
the age represent the number of mice examined. (C) Sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis of
urinary protein. Urine samples (2 lL) from HIV13FVB, HIV13B6 and
wild-type (W) mice were analyzed at the ages indicated.
analysis. The penetrance rate of the nephropathy in this
study was 86%. No wild-type littermates showed abnor-
mality. Some HIV13FVB mice showed a small amount of
ascites before the death. At 3 weeks of age, blood urea
nitrogen (BUN) was elevated to 154.0 ± 50.9 mg/dL in
HIV13FVB mice (N = 6) vs. 18.6 ± 1.7 mg/dL in wild-type
littermates (N = 6) (P < 0.05).
Genetic predisposition to nephropathy
In contrast to HIV13FVB mice, most HIV13B6 mice
showed no or only mild and slowly progressive nephropa-
thy. Since mature wild-type male mice excrete a relatively
high amount of protein in urine, the incidence of pro-
teinuria was assessed in female mice. Only three of the
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Fig. 4. Survival rates for HIV13FVB and HIV13B6 mice. HIV13FVB
mice (N = 14), their wild-type littermates (N = 14), HIV13B6 mice
(N = 55), and their wild-type littermates (N = 50) were longitudinally
followed up to 18 weeks of age. No mice died in either wild-type group,
over the time span. Ten HIV13FVB mice died by 18 weeks of age,
and they all showed severe glomerulosclerosis. Of the four HIV13FVB
mice that survived for 18 weeks, two showed moderate focal segmental
glomerulosclerosis (FSGS), and the other two showed normal renal
histology.
Table 3. Glomerular maturity indices in HIV13FVB and wild-type
littermates at 2 weeks of age
Transgenic
(HIV13FVB) Wild-type
Genotype (N = 4) (N = 5) P value
Total cortex 1.42 ± 0.02 1.54 ± 0.07 <0.05
Outer cortex 1.28 ± 0.04 1.40 ± 0.10 <0.05
Inner cortex 1.56 ± 0.03 1.66 ± 0.05 <0.05
21 (14%) HIV13B6 female mice showed overt nonse-
lective proteinuria, and five HIV13B6 mice showed mild
albuminuria by 6 weeks of age (Fig. 3B and C). Of the 55
HIVB6 mice followed longitudinally for 18 weeks, only
four mice died between 4 and 13 weeks of age (Fig. 4).
When HIV13B6 mice were backcrossed with C57BL/6
mice three more times, none of the transgenic offspring
(N = 12) developed nephropathy by 10 months of age.
When the backcrossed mice were mated again with
FVB/N mice, 10 out of 12 transgenic offspring developed
severe nephropathy by 6 weeks of age.
Renal lesions in HIV13FVB mice
Before the appearance of proteinuria, no glomerular
damage was observed in HIV13FVB mice by light mi-
croscopy. In wild-type mice, glomerular maturation was
completed after 3 weeks of age. However, in HIV13FVB
mice around the onset of proteinuria, glomeruli were of-
ten found to have reduced branching of capillaries. We
semiquantified the glomerular maturation in 2 weeks old
HIV13FVB mice (0 to 3+ score) (Table 3). In both the
inner and outer cortices, the glomerular maturity score
in HIV13FVB mice was significantly lower than that in
wild-type littermates.
A B
Fig. 5. Glomerular morphology around the onset of proteinuria. Wild-
type (A) and HIV13FVB (B) at 3 weeks of age. Glomeruli in
HIV13FVB mice often showed decreased branching of capillaries,
and cuboidal-shaped podocytes [synaptopodin and periodic acid-Schiff
(PAS) staining ×400].
In addition to the immaturity of the glomerular struc-
ture, podocytes also showed immature morphology in
HIV13FVB mice. In mature glomeruli of wild-type mice,
podocyte cell bodies were mature with extended cyto-
plasm along the basement membrane. In contrast, more
than 50% of glomeruli of HIV13FVB mice showed
cuboidal podocytes with plump undifferentiated cell
bodies as opposed to flat cell bodies of differenti-
ated podocytes. Cuboidal podocytes were observed un-
til shortly after the onset of proteinuria (Fig. 5) before
podocytes were damaged.
Electron microscopy at 3 weeks of age in HIV13FVB
mice showed podocyte degeneration with vacuoles and
blunted or completely effaced foot processes. The lamina
rara externa, but not interna, of the glomerular basement
membrane (GBM) exhibited an abnormal scalloped ap-
pearance. In some severely damaged glomeruli, there
were subendothelial electron-dense deposits. Endothe-
lial cells were abnormally swollen. Mesangial cells were
increased in number, and early mesangiolysis was occa-
sionally observed. Parietal epithelial cells and proximal
tubular cells lining Bowman’s capsule were injured with
vacuolar changes and occasional necrosis (Fig. 6A).
To analyze the morphology of podocytes further in de-
tail, we observed kidney tissues with scanning electron
microscopy at 3 weeks of age (Fig. 6B and C). In wild-
type glomeruli, podocytes had fully developed primary
processes, with full development of secondary processes,
and the GBM was covered by mature foot processes. In
glomeruli of HIV13FVB mice, most surface areas of the
GBM were covered by cuboidal podocyte cell bodies and
the area covered by foot processes was markedly reduced.
Moreover, numerous microvilli were observed on the sur-
face of podocytes.
In contrast, HIV13B6 mice showed no immaturity of
glomerular architecture or podocyte morphology.
After the onset of proteinuria, most remarkable
changes were vacuolar degeneration of podocytes and
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Fig. 6. Glomerular structure at 3 weeks of age. (A) Transmission elec-
tron microscopy of the kidneys of HIV13FVB mice. Podocytes (P)
showed degeneration with huge vacuoles, with complete effacement
of foot processes. The glomerular basememnt membrane was irregu-
larly scalloped. Endothelial cells (E) were swollen. M is mesangial cell.
Bars represent 1 lm. (B and C) Scanning electron microscopy of the
glomeruli from wild-type (B) and HIV13FVB (C) mice. In wild-type
mice, primary processes and foot processes of podocytes were well de-
veloped, whereas in HIV13FVB mice, only podocyte cell bodies, with
microvillous transformation, were observed. Bars represent 1 lm.
parietal epithelial cells (Figs. 7D and 8F). Both flat and
proximal tubular cell-type parietal epithelial cells were
affected. Podocytes and parietal epithelial cells often con-
tained protein reabsorption droplets, adhered to each
other and were intermingled. Immunostaining revealed
that synaptopodin and WT-1, markers for podocytes,
were markedly reduced in damaged glomeruli (Fig. 8H
and I). Some podocytes stained positive for desmin, a
marker of damaged podocytes (Fig. 8J and K).
Glomerular epithelial cells proliferated and filled Bow-
man’s space. In some glomeruli, they formed fibrocellular
crescents. Most of these cells in Bowman’s space, except
for those directly attached to the GBM, stained positive
for cytokeratin, a marker of parietal epithelial cells, but
not for synaptopodin, a marker of podocytes (Fig. 8G
and H). Some cytokeratin-positive and desmin-negative
cells were located on the outer surface of the GBM
(Fig. 8K and L). Cytokeratin and desmin staining did
not overlap each other (i.e., no glomerular cells was dou-
bly positive). Ki-67 positivity, a proliferation marker cell,
was mainly present in parietal epithelial cells (Fig. 9B).
Although rare, cytokeratin-negative and synaptopodin-
positive podocytes piled up forming two layers in some
glomeruli of young HIV13FVB mice, while parietal ep-
ithelial cells appeared quite quiescent (Fig. 9C and D).
However, Ki-67 was not detected in these cells, indicat-
ing that they were not in proliferating phase at the time
of sacrifice.
Soon after the onset of proteinuria, expansion of
mesangial matrix, with an increase in collagen (data not
shown), was observed and intensified with time. In some
mice, mesangial hyperplasia was observed. After 4 weeks
of age, HIV13FVB mice developed glomerulosclerosis
(Figs. 7D and 10B) with focal segmental collapse. In the
later phase of disease progression, mesangial matrix con-
tained intensely periodic acid-Schiff (PAS)–positive ma-
terials, which often stained positive for IgG, IgM, and
fibrinogen (data not shown).
In parallel with proteinuria, proteinaceous casts ac-
cumulated in tubular lumens. After 6 weeks of age,
HIV13FVB mice showed interstitial fibrosis and dif-
fuse tubular dilatation with focal microcystic lesions
(Fig. 7C). Tubular and interstitial cells in HIV13FVB
mice showed more intensive proliferation than glomeru-
lar cells, indicated by Ki-67 staining (Fig. 9B), and apopto-
sis, as depicted by terminal deoxynucleotidyl transferase
(TdT)-mediated deoxyuridine triphosphate (dUTP) nick
end labeling (TUNEL) staining (data not shown).
Renal lesions in HIV13B6 mice
Most HIV13B6 mice survived more than 6 months af-
ter birth. Of the 12 HIV13B6 mice histologically ana-
lyzed after 6 months of age, four (33%) were completely
normal. Two showed advanced FSGS and tubular dilata-
tion and interstitial fibrosis. The other six mice (50%)
showed focal intratubular casts and mild mesangial ex-
pansion and, occasionally, glomerular sclerosis (Fig. 7E
and F). No HIV13B6 mice showed collapsing FSGS le-
sions or vacuolar degeneration of podocytes.
DISCUSSION
In the present study, we generated transgenic mice
that express nonstructural HIV-1 genes selectively in
podocytes. The transgenic mice showed injury not only
in podocytes but also in other renal cells, developed col-
lapsing FSGS and microcystic tubular dilatation and died
from renal failure.
Four of the seven transgenic mice subjected to anal-
ysis developed collapsing FSGS in the founders or their
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Fig. 7. Renal lesions of HIV13 transgenic mice. (A and B) Wild-type littermates of HIV13FVB mice at 6 weeks of age showed normal histology.
(C and D) HIV13FVB mice at 6 weeks of age showed microcystic dilatation of tubules (C) and global or segmental glomerulosclerosis, collapsing
glomerulosclerosis (D, arrow), and vacuolar degeneration of glomerular epithelial cells (D, arrowheads). (E and F) HIV13B6 mice at 6 months of
age showed focal segmental glomerulosclerosis (FSGS) and mesangial expansion [periodic acid-Schiff (PAS) staining ×100 (A, C, and E) and ×200
(B, D, and F)].
offspring. Two factors should be considered regarding the
incomplete penetrance of nephropathy. First, the pene-
trance rate of transgene expression by the nephrin pro-
moter is not always 100%. Thus far, we have generated
several other transgenic mice and observed that the rate
of renal expression of the transgene ranged from about
20% to 80% [47] (unpublished observations). A sec-
ond key factor is genetic background. The development
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Fig. 8. Damage of glomerular epithelial cells in HIV13FVB mice. Wild-type (A to E) and HIV13FVB (F to L) mice at 4 weeks of age. Note the
prominent proliferation and degeneration of epithelial cells with cytokeratin immunoactivity, a marker for parietal epithelial cells, with markedly
reduced synaptopodin and WT-1, podocyte markers (F to I vs. A to D). In wild-type mice, desmin was faintly detectable only in mesangial cells
(E), whereas in HIV13FVB mice, desmin was expressed in podocytes (J). Staining for desmin (K) and cytokeratin (L) in adjacent sections revealed
that some visceral epithelial cells were negative for desmin and positive for cytokeratin. No cells were doubly positive for desmin and cytokeratin
[periodic acid-Schiff (PAS) staining (A and F) and immunostaining for cytokeratin (B, G, and L), synaptopodin (C and H), WT-1 (D and I) or
desmin (E, J, and K) (A to E, E to F, K and L, respectively, are adjacent sections (×400)].
Fig. 9. Cell proliferation in wild-type and
HIV13FVB mice. (A and B) In wild-type mice
(A), a rare Ki-67 staining is indicated with ar-
rows. Ki-67 in tubular and glomerular parietal
epithelial cells was increased in HIV13FVB
mice (B). Immunostaining for Ki-67 with
counterstaining by periodic acid-Schiff (PAS)
in wild-type (A) and HIV13FVB mice (B)
(×200). (C and D) Apparent proliferation
of podocytes in HIV13FVB mice. In some
glomeruli of HIV13FVB mice, podocytes
piled up, forming two layers. PAS (C) and
synaptopodin (D) staining in the adjacent sec-
tion (×400).
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Fig. 10. Glomerulosclerosis in wild-type and HIV13FVB mice. Wild-
type (A) and HIV13FVB (B) mice at 4 weeks of age. In HIV13FVB
mice (B), glomeruli show noncollapsing segmental sclerosis (arrow) and
collapsing sclerosis (arrowhead) [silver staining (×400)].
of nephropathy in the Tg26 line highly depends on the
FVB genetic background [48]. The founder transgenic
mice of the present study had a mixed genetic back-
ground of C57BL/6 and DBA/2, both of which are re-
sistant to Tg26-induced nephropathy. Of the three trans-
genic mice that did not show proteinuria, two mice did
not express the transgene in the kidney. The other mouse
expressed the transgene in the kidney, but was infertile,
therefore, this line could not be analyzed on the FVB
genetic background.
HIV-1 virus encodes nine genes. Among those genes,
accumulating data indicate that nef and vpr are involved
in the pathogenesis of HIVAN. HIV-1 transgenic ani-
mals lacking pol and gag develop renal lesions similar
to HIVAN [23, 32, 34–37, 39, 41, 49]. Kajiyama et al [50]
reported that a transgenic mouse line expressing HIV-1
genes lacking gag, pol, and nef under the control of its
own promoter developed FSGS, and that genetic com-
plementation with nef substantiated FSGS. Dickie et al
[49] reported that transgenic mouse lines expressing vpr
in the kidney, under the regulation of its own promoter
or of the c-fms promoter, but not those lacking vpr, de-
veloped FSGS [49]. However, the CD4C/HIVtransgenic
mice expressing nef with the CD4 regulatory elements
also develop FSGS and interstitial nephritis [37, 45]. In
addition, in vitro experiments showed that nef induces
proliferation, anchorage-independent growth and dedif-
ferentiation of podocytes [51, 52]. These results collec-
tively indicate that vpr and nef can each induce FSGS.
However, the pathogenicity of these two gene products
may depend on the cell population in which they are ex-
pressed. Indeed, vpr could not induce nephropathy when
expressed under the regulation of the CD4C promoter,
while nef was very efficient at doing so [37]. Moreover, it
appears that nef potentiates the development of glomeru-
losclerosis by vpr when expressed under the LTR pro-
moter, possibly in podocytes. In the transgenic mice stud-
ied here, both vpr and nef were expressed in podocytes
and may be collaborating to induce nephropathy, a notion
consistent with the previous suggestions. Our transgenic
mice do not carry env, gag, and pol, confirming that these
viral gene products are not involved in the pathogenesis
of HIVAN.
In our transgenic mice, we used a podocyte-specific
nephrin promoter. Indeed, HIV-1 mRNA was detected
in podocytes by in situ hybridization. As predicted,
podocytes were severely injured in HIV13FVB mice.
Podocyte injury was identified by light microscopy,
transmission electron microscopy, scanning electron
microscopy, and immunostaining. In addition, other
glomerular cells, including mesangial cells, glomerular
endothelial cells, and parietal epithelial cells, were also
injured. Similar renal pathologies were observed in an-
other podocyte-selective injury model (NEP25) that we
recently developed [47]. NEP25 is a transgenic mouse
line expressing human (h) CD25 selectively in podocytes.
Injection of an immunotoxin specific to hCD25 allowed
us to induce podocyte-specific injury. After the injection
of the immunotoxin, NEP25 mice showed injuries not
only in podocytes, but also in other glomerular cells, in-
cluding endothelial cells, mesangial cells, and parietal ep-
ithelial cells, and developed glomerulosclerosis. In ad-
dition to glomerular damage, NEP25 mice developed
tubulointerstitial injuries, including microcystic tubular
dilatation. HIV13FVB mice and NEP25 mice share a
number of similar pathologic features, namely vacuoliza-
tion of podocytes and parietal epithelial cells, prolifera-
tion of parietal epithelial cells, expansion of mesangial
matrix, mesangiolysis, swelling of glomerular endothe-
lial cells, hyalinosis, glomerular sclerosis, deposition of
immunoglobulins in a later phase, and tubulointerstitial
injuries. These phenotypes, therefore, appear to be the
common outcomes triggered by podocyte injury. On the
other hand, collapse of glomerular capillaries, immature
morphology of the glomerulus and podocytes and rare
proliferation of podocytes were unique to HIV13 trans-
genic mice.
Similar to Tg26 mice, HIV13FBV mice showed avid
cell proliferation within Bowman’s space. These extra-
capillary proliferating cells and parietal epithelial cells
lining Bowman’s capsule were often positive for Ki-67,
whereas the cells adjacent to the GBM were rarely pos-
itive for Ki-67. Most cells proliferating distant from the
GBM were positive for cytokeratin, a marker of parietal
epithelial cells. Synaptopodin, when it was not completely
down-regulated, was detected only in cells adjacent to
the GBM. We found no cells doubly positive for synap-
topodin and Ki-67. These findings indicate that most cells
proliferating in Bowman’s space were derived from pari-
etal epithelial cells, as suggested in some studies on hu-
man nephropathy [53, 54]. The possibility, however, can-
not be ruled out that podocytes changed phenotype and
also acquired proliferative capability. In fact, although
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very rare, we identified occasional podocytes by synap-
topodin staining that had piled up and formed two lay-
ers, suggesting podocyte proliferation. Some desmin-
negative and cytokeratin-positive cells were located on
the outer surface of the GBM. Despite extensive search,
we found no cells doubly positive for desmin and cytok-
eratin. These indicate that parietal epithelial cells may
migrate and locate at the visceral site, rather than that
podocytes undergo phenotypic transition.
The reason why podocyte proliferation was rare in
HIV13FVB mice remains unclear. The possibility exists
that the expression of HIV-1 transgene, driven by the
nephrin promoter, may be quickly down-regulated when
podocytes change their phenotype. In fact, HIV-1 mRNA
was not detected by RT-PCR in kidneys with severe le-
sions (data not shown). Likewise, studies in Tg26 mice
showed that HIV-1 transgene expression, driven by the
authentic HIV-1 promoter, LTR, was down-regulated in
the end stage of the disease [32]. The timing and extent
of down-regulation of the promoter may cause different
phenotypes regarding podocyte hyperplasia.
Around the onset of proteinuria, podocytes of
HIV13FVB mice showed a pattern of morphologic im-
maturity along with scalloped GBM. Although not a typ-
ical finding in HIVAN, scalloped GBM has been observed
in some pediatric kidneys transplanted into adults [55].
Changes in hemodynamics or growth, that occurred when
the small immature kidney is transplanted into the adult,
may cause these unusual lesions. The immature podocytes
were devoid of extension of primary processes and foot
processes. This observation, together with the fact that
HIV-1 proteins, including Nef and Vpr, can associate with
cytoskeleton and alter cell shape, lead us to the follow-
ing speculation on the development of renal lesions in
HIV13FVB mice. HIV-1 gene products may affect the cy-
toskeleton or other cellular components and inhibit the
projection of processes. This abnormality of podocytes
may in turn cause decreased branching of glomerular cap-
illaries, a lesion often observed in HIV13FVB mice. These
abnormal podocytes also cannot function as an effective
filtration barrier, resulting in massive proteinuria. Pro-
teinuria, or other abnormalities that occur after the onset
of proteinuria, may cause secondary damage to podocytes
and other renal cells as seen in NEP25 mice, ultimately
leading to glomerulosclerosis.
In addition to glomerular damage, HIV13FVB mice
also developed tubulointerstitial injuries, similar to
NEP25 mice [47]. In a later phase, tubular microcystic
lesions developed. In human kidneys with HIVAN or
those of Tg26 mice, but not in CD4C/HIV transgenic
mice, HIV-1 DNA and RNA were detected in tubu-
lar cells [25–27, 38, 42]. Bruggeman et al [34] reported
that up-regulation of the transgene by ultraviolet light
irradiation-induced apoptosis of tubular cells in cultured
renal tissues of Tg26 mice, indicating that HIV-1 gene
products have direct toxic effects on renal tubular cells.
In this regard, our present observations with podocyte-
restricted expression of HIV-1 genes suggest that the
tubular and interstitial alterations in HIV13FVB mice,
quite like those in NEP25 mice, are secondary to glomeru-
lar deterioration triggered by podocyte injury, and further
verify the capacity of podocyte injury to bring about the
progression of HIVAN.
Development of HIVAN in HIV-1 infected patients
shows a strong racial predilection for black and Hispanic
patients. Similarly, the development of nephropathy in
Tg26 line is highly dependent on FVB/N genetic back-
ground, although the transgene expression level is not en-
hanced by FVB/N genetic background. The locus for the
susceptibility to nephropathy in mice has been mapped to
chromosome 3A1-3 [48]. Development of nephropathy
in the HIV13 line also showed a strong genetic predilec-
tion for FVB/N genetic background. Thus, the founder
HIV13 had, on average, 75% of C57BL/6 and 25% of
DBA/2 genetic background, and showed very mild renal
lesions without overt proteinuria. Most HIV13FVB mice
showed severe nephropathy after 3 weeks of age, while
most HIV13B6 mice showed either no or very mild renal
lesions. When HIV13B6 mice were further backcrossed
with C57BL/6 mice four times, none of the transgenic off-
spring showed abnormality in the kidney. These findings
indicate that irrespective of the promoter driving HIV-1
genes, FVB/N genetic background enhances the progres-
sion of the renal disease caused by HIV-1 gene products.
Some HIV13B6 mice showed mild and less progressive
renal lesions. These lesions mainly consisted of mesan-
gial changes, and no vacuolar degeneration of podocytes
was observed. We also observed a similar phenomenon in
NEP25 mice injected with a small dose of immunotoxin
[47]. In these NEP25 mice, the main lesion was mesan-
gial expansion, and vacuolization of podocytes was less
remarkable. Interestingly, mesangial change is frequently
observed in HIVAN, especially in children, and HIV-1–
infected patients with mesangial lesions show a slower
rate of the progression of the renal disease than those with
FSGS [30]. It is conceivable that HIV-1-induced podocyte
dysregulation is the central mechanism of the full spec-
trum of HIVAN, whereas the above atypical renal com-
plications develop under the influence of genetic factors.
CONCLUSION
We demonstrate that the expression of HIV-1 genes se-
lectively in podocytes alone is sufficient for the develop-
ment of the full spectrum of typical and atypical HIVAN.
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